CTIS2023-503208-94-00招募中1 期
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer - CAAA617A12402
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 704
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Must have received at least one dose of AAA617 within an interventional, phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them to participate in this study.
排除标准
- •Inability to complete the needed investigational examinations due to any reason.
研究者
相似试验
进行中（未招募）
4 期
To assess safety and effectiveness of Rivaroxaban(Xarelto)in managing coronary and or symptomatic peripheral artery disease in Indian PatientsCTRI/2022/01/039597Bayer Zydus Pharma Pvt Ltd
进行中（未招募）
不适用
Post-authorization safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human erythropoietin alfa i.v. - NDEUCTR2007-005728-34-ITHEXAL BIOTECH1,500
尚未招募
4 期
A study to check safety and efficacy of Pregabalin Prolonged Release and Etoricoxib Tablet in patients with Chronic Low Back Pain Associated with Neuropathic ComponentCTRI/2022/05/042521Sun Pharma Laboratory Limited SP
进行中（未招募）
1 期
Post-authorization Phase IV effectiveness and safety multicentric study of COVID-19 vaccines – CoVigiEUCTR2021-000566-14-CZMasarykova univerzita565
已完成
4 期
Phase IV, Open-label Study to Assess the Safety of H5N1 Pre-pandemic Vaccine (BK-KIB-01)JPRN-jRCT1090220019ational Hospital Organization Mie National Hospital6,000